Why Did Carlos Slim Buy PBF Energy?
Carlos Slim made a splash in a surprising sector last…
Sell
47
DRUG Quote, Financials, Valuation and Earnings
Last price:
$38.32
Seasonality move
:
-32.13%
Day range:
$34.79 - $42.47
52-week range:
$0.93 - $79.02
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
70.12x
Volume:
148.1K
Avg. volume:
139.8K
1-year change:
2135.94%
Market cap:
$287.3M
Revenue:
--
EPS (TTM):
-$0.68
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences
|
-- | -- | -- | -- | -- |
|
IBIO
iBio
|
-- | -$0.45 | -100% | -89.82% | -- |
|
JNJ
Johnson & Johnson
|
$22.5B | $2.04 | 4.96% | 22% | $174.71 |
|
NBY
NovaBay Pharmaceuticals
|
$2.5M | -$0.24 | -60.77% | -99.16% | $7.30 |
|
PTN
Palatin Technologies
|
-- | -$0.42 | -100% | -25% | -- |
|
TOVX
Theriva Biologics
|
-- | -$5.50 | -- | -8.25% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences
|
$41.11 | -- | $287.3M | -- | $0.00 | 0% | -- |
|
IBIO
iBio
|
$2.42 | -- | $22.1M | -- | $0.00 | 0% | -- |
|
JNJ
Johnson & Johnson
|
$144.02 | $174.71 | $346.7B | 23.81x | $1.24 | 3.38% | 3.99x |
|
NBY
NovaBay Pharmaceuticals
|
$0.63 | $7.30 | $3.1M | -- | $0.00 | 0% | 0.07x |
|
PTN
Palatin Technologies
|
$1.30 | -- | $25.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics
|
$1.65 | -- | $4.6M | -- | $0.00 | 0% | 1.59x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences
|
-- | -104.564 | -- | -- |
|
IBIO
iBio
|
4.41% | 8.236 | 5.41% | 3.89x |
|
JNJ
Johnson & Johnson
|
33.76% | 0.772 | 9.16% | 0.70x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.365 | 1.51% | 0.75x |
|
PTN
Palatin Technologies
|
-- | -3.016 | -- | 0.99x |
|
TOVX
Theriva Biologics
|
-- | -1.870 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences
|
-- | $171.5K | -- | -- | -- | $193K |
|
IBIO
iBio
|
-- | -$4.1M | -90.99% | -148.3% | -1820.57% | -$3.7M |
|
JNJ
Johnson & Johnson
|
$15.5B | $5.3B | 14.07% | 20.88% | 15.71% | $5.7B |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
PTN
Palatin Technologies
|
$350K | -$7.8M | -- | -- | -2356.3% | -$7M |
|
TOVX
Theriva Biologics
|
-- | -$5M | -- | -- | -- | -$3.9M |
Bright Minds Biosciences vs. Competitors
-
Which has Higher Returns DRUG or IBIO?
iBio has a net margin of -- compared to Bright Minds Biosciences's net margin of -4444.57%. Bright Minds Biosciences's return on equity of -- beat iBio's return on equity of -148.3%.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences-- $0.04 -- IBIOiBio-- -$0.46 $22.3M -
What do Analysts Say About DRUG or IBIO?
Bright Minds Biosciences has a consensus price target of --, signalling downside risk potential of --. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 48.76%. Given that iBio has higher upside potential than Bright Minds Biosciences, analysts believe iBio is more attractive than Bright Minds Biosciences.
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences0 0 0 IBIOiBio0 0 0 -
Is DRUG or IBIO More Risky?
Bright Minds Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iBio has a beta of -3.266, suggesting its less volatile than the S&P 500 by 426.584%.
-
Which is a Better Dividend Stock DRUG or IBIO?
Bright Minds Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or IBIO?
Bright Minds Biosciences quarterly revenues are --, which are smaller than iBio quarterly revenues of $175K. Bright Minds Biosciences's net income of $168K is higher than iBio's net income of -$4M. Notably, Bright Minds Biosciences's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences is -- versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences-- -- -- $168K IBIOiBio-- -- $175K -$4M
-
Which has Higher Returns DRUG or JNJ?
Johnson & Johnson has a net margin of -- compared to Bright Minds Biosciences's net margin of 11.99%. Bright Minds Biosciences's return on equity of -- beat Johnson & Johnson's return on equity of 20.88%.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences-- $0.04 -- JNJJohnson & Johnson69.01% $1.11 $105.9B -
What do Analysts Say About DRUG or JNJ?
Bright Minds Biosciences has a consensus price target of --, signalling downside risk potential of --. On the other hand Johnson & Johnson has an analysts' consensus of $174.71 which suggests that it could grow by 21.01%. Given that Johnson & Johnson has higher upside potential than Bright Minds Biosciences, analysts believe Johnson & Johnson is more attractive than Bright Minds Biosciences.
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences0 0 0 JNJJohnson & Johnson8 13 0 -
Is DRUG or JNJ More Risky?
Bright Minds Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.512, suggesting its less volatile than the S&P 500 by 48.827%.
-
Which is a Better Dividend Stock DRUG or JNJ?
Bright Minds Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.38% to investors and pays a quarterly dividend of $1.24 per share. Bright Minds Biosciences pays -- of its earnings as a dividend. Johnson & Johnson pays out 33.48% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios DRUG or JNJ?
Bright Minds Biosciences quarterly revenues are --, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Bright Minds Biosciences's net income of $168K is lower than Johnson & Johnson's net income of $2.7B. Notably, Bright Minds Biosciences's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 23.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences is -- versus 3.99x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences-- -- -- $168K JNJJohnson & Johnson3.99x 23.81x $22.5B $2.7B
-
Which has Higher Returns DRUG or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to Bright Minds Biosciences's net margin of -49.65%. Bright Minds Biosciences's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences-- $0.04 -- NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About DRUG or NBY?
Bright Minds Biosciences has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 496%. Given that NovaBay Pharmaceuticals has higher upside potential than Bright Minds Biosciences, analysts believe NovaBay Pharmaceuticals is more attractive than Bright Minds Biosciences.
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences0 0 0 NBYNovaBay Pharmaceuticals2 0 0 -
Is DRUG or NBY More Risky?
Bright Minds Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.
-
Which is a Better Dividend Stock DRUG or NBY?
Bright Minds Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or NBY?
Bright Minds Biosciences quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Bright Minds Biosciences's net income of $168K is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Bright Minds Biosciences's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences-- -- -- $168K NBYNovaBay Pharmaceuticals0.07x -- $2.4M -$1.2M
-
Which has Higher Returns DRUG or PTN?
Palatin Technologies has a net margin of -- compared to Bright Minds Biosciences's net margin of -2357.27%. Bright Minds Biosciences's return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences-- $0.04 -- PTNPalatin Technologies-- -$0.39 -$111.5K -
What do Analysts Say About DRUG or PTN?
Bright Minds Biosciences has a consensus price target of --, signalling downside risk potential of --. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1207.69%. Given that Palatin Technologies has higher upside potential than Bright Minds Biosciences, analysts believe Palatin Technologies is more attractive than Bright Minds Biosciences.
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences0 0 0 PTNPalatin Technologies0 0 0 -
Is DRUG or PTN More Risky?
Bright Minds Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.
-
Which is a Better Dividend Stock DRUG or PTN?
Bright Minds Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or PTN?
Bright Minds Biosciences quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Bright Minds Biosciences's net income of $168K is higher than Palatin Technologies's net income of -$7.8M. Notably, Bright Minds Biosciences's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences-- -- -- $168K PTNPalatin Technologies-- -- $350K -$7.8M
-
Which has Higher Returns DRUG or TOVX?
Theriva Biologics has a net margin of -- compared to Bright Minds Biosciences's net margin of --. Bright Minds Biosciences's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences-- $0.04 -- TOVXTheriva Biologics-- -$6.81 -- -
What do Analysts Say About DRUG or TOVX?
Bright Minds Biosciences has a consensus price target of --, signalling downside risk potential of --. On the other hand Theriva Biologics has an analysts' consensus of -- which suggests that it could grow by 5384.85%. Given that Theriva Biologics has higher upside potential than Bright Minds Biosciences, analysts believe Theriva Biologics is more attractive than Bright Minds Biosciences.
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences0 0 0 TOVXTheriva Biologics0 0 0 -
Is DRUG or TOVX More Risky?
Bright Minds Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.367%.
-
Which is a Better Dividend Stock DRUG or TOVX?
Bright Minds Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or TOVX?
Bright Minds Biosciences quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Bright Minds Biosciences's net income of $168K is higher than Theriva Biologics's net income of -$7.7M. Notably, Bright Minds Biosciences's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences is -- versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences-- -- -- $168K TOVXTheriva Biologics1.59x -- -- -$7.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Booking Holdings Stock Undervalued?
There is a lot of humdrum in the market about…
Broadcom vs American Express: Which Is Best?
Chip giant Broadcom Inc. (NASDAQ:AVGO) and card company American Express…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 116x
Sell
43
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Sell
47
DRUG alert for Jan 3
Bright Minds Biosciences [DRUG] is down 4.72% over the past day.
Buy
88
BMA alert for Jan 3
Banco Macro SA [BMA] is up 0.71% over the past day.
Sell
50
AGFY alert for Jan 3
Agrify [AGFY] is down 5.83% over the past day.
